EXOSOME-BASED LIQUID BIOPSY
Craif is a pioneer in exosome-based liquid biopsy for accurate and unpainful early cancer detection.
We aim to create a society where everyone can stay healthy throughout their lifetime.
The Number of Medical Institution Installing miSignal®️, a Cancer Risk Screening Test, Achieves 300
Craif Starts Offering New Product in “miSignal®️” Series, “Remote Cancer TestTM”
Craif Announces New Product in “miSignal®️” Series, “Remote Cancer TestTM” with Adding Three Additional Cancer Types (Pancreatic, Colorectal, and Esophageal) to the Lineup
Craif Launches Breast Cancer Test from “miSignal®️” Series Which Enables Early-stage Cancer Detection Using Urinary miRNA
Enrichment of exosomes from body fluid efficiently with a simple procedure allows a more accurate interpretation of cellular communications
miSignal ® is a screening test to determine your risk of developing cancers. It determines cancer risk by utilizing the difference in the expression patterns of microRNAs in the urine of cancer patients and in that of healthy individuals.
